SMO inhibitors such as vismodegib, IPI-926 and sonidegib showed high efficacy in cancer types like basal cell carcinoma or medulloblastoma that often harbor activating mutations in the HH pathway. The gene discussed is SMO; the disease is basal cell carcinoma.